We're making nearly 300% gains on a rising pharmaceutical stock
Shortly after the opening bell, we will sell 10 shares of Eli Lilly at approximately $958 each. Following Monday's trade,…
Jim Cramer
Jim Cramer discusses the reasons for the market crash and three factors that influenced stock performance
Each weekday, CNBC's Investment Club with Jim Cramer publishes the final stretch, an action-packed afternoon update just in time for…
Jim Cramer says Vornado's double modernization is a sign that the city's real estate sector is back
Jim Cramer's daily quick analysis of stocks making the news outside of the CNBC Investing Club portfolio. Lowe's: The home…
GEHC gives reasons to look beyond China's temporary woes and stocks rise again
GE Healthcare reported a mixed second quarter on Wednesday morning, and shares initially dipped sharply. Shares then reversed higher as…
A bullish bet on major banks is lost in the rotation of technology stocks
Each weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
We are encouraged by Abbott's stock performance, but discouraged by the moves at Honeywell
Every weekday, the CNBC Investment Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
How to trade Abbott stock after the nearly $500 million infant formula verdict
Every weekday, the CNBC Investment Club with Jim Cramer hosts a live “Morning Meeting” broadcast at 10:20 a.m. ET. Here's…
Cut 2 stocks and buy 2 other laggards
On Monday morning, we will execute four trades. Shortly after the opening bell, we will sell 100 shares of Danaher…
A poor earnings report from a competitor is good news for Abbott Labs
Every weekday, the CNBC Investment Club with Jim Cramer hosts a live “Morning Meeting” broadcast at 10:20 a.m. ET. Here’s…
FDA approval of Eli Lilly's Alzheimer's drug cements our decision not to profit
Each weekday, the CNBC Investment Club with Jim Cramer publishes The Home Stretch, a handy evening update, just in time…